AMPHETAMINE SULFATE - Generic Drug Details

What are the generic sources for amphetamine sulfate and what is the scope of freedom to operate?

Amphetamine sulfate is the generic ingredient in three branded drugs marketed by Azurity, Alkem Labs Ltd, Amneal Pharms, Aurolife Pharma Llc, Bionpharma, Dr Reddys Labs Sa, Epic Pharma Llc, Glenmark Pharms Ltd, Granules, Lannett, Novast Labs, Prinston Inc, Rhodes Pharms, Sanaluz, Senores Pharms, Specgx Llc, and Sun Pharm Inds Inc, and is included in eighteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for amphetamine sulfate. Eleven suppliers are listed for this compound.

Summary for AMPHETAMINE SULFATE

US Patents:	3
Tradenames:	3
Applicants:	17
NDAs:	18
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	8
Patent Applications:	2,299
Drug Prices:	Drug price trends for AMPHETAMINE SULFATE
What excipients (inactive ingredients) are in AMPHETAMINE SULFATE?	AMPHETAMINE SULFATE excipients list
DailyMed Link:	AMPHETAMINE SULFATE at DailyMed

See drug prices for AMPHETAMINE SULFATE

Recent Clinical Trials for AMPHETAMINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vallon Pharmaceuticals, Inc.	Phase 1
Arbor Pharmaceuticals, Inc.	Phase 3
Sarah Morrow	Phase 2/Phase 3

See all AMPHETAMINE SULFATE clinical trials

Pharmacology for AMPHETAMINE SULFATE

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for AMPHETAMINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	214574-001	Jan 27, 2021		DISCN	No	No
Bionpharma	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	212919-001	Nov 22, 2019	AA	RX	No	No
Azurity	EVEKEO	amphetamine sulfate	TABLET;ORAL	200166-002	Aug 9, 2012	AA	RX	No	Yes
Amneal Pharms	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	211139-001	Sep 26, 2018	AA	RX	No	No
Sanaluz	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	212582-002	Feb 4, 2020	AA	RX	No	No
Novast Labs	AMPHETAMINE SULFATE	amphetamine sulfate	TABLET;ORAL	213763-001	Aug 24, 2020		DISCN	No	No
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-002	Jan 30, 2019		DISCN	Yes	No	10,441,554		Y

Expired US Patents for AMPHETAMINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-004	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-005	Apr 16, 2021	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-002	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-003	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019	10,130,580

Summary

Last updated: February 13, 2026

Amphhetamine sulfate remains a significant agent within the pharmaceutical landscape. Its market size, growth rate, and competitive positioning reflect evolving regulations, clinical indications, and manufacturing capacity. The drug's market dynamics are characterized by widespread medical use, high production volumes, and regulatory oversight, supporting a steady financial trajectory.

---

What Are the Current Market Sizes and Volumes for Amphhetamine Sulfate?

Global production of amphetamine sulfate compounds exceeds 100 metric tons annually, with the United States accounting for approximately 60% of the market volume. The Drug Enforcement Agency (DEA) reports that in 2022, the U.S. legal manufacture and distribution of amphetamine salts reached approximately 60,000 kilograms, indicating high utilization levels driven primarily by prescriptions for ADHD and narcolepsy.

The global pharmaceutical market for stimulant medications, including amphetamines, has a valuation of approximately $5-7 billion, with Amphetamine Sulfate constituting around 50%, given its dominance in prescriptions for ADHD (estimated at 2.4 million prescriptions annually in the U.S.) and narcolepsy treatments.

How Is the Market for Amphetamine Sulfate Organized?

The market consists of multiple segments:

• Manufacturers: Major companies include TEVA Pharmaceutical Industries, Mallinckrodt Pharmaceuticals, and Sandoz, which produce pharmaceutical-grade amphetamine sulfate and salts.

• Regulatory Bodies: The DEA enforces quotas for production in the U.S., primarily via the Controlled Substances Act (CSA). Similar controls are enacted by the European Medicines Agency (EMA) and other national agencies.

• Distribution Channels: Wholesale drug suppliers, pharmacies, and hospital systems predominantly distribute amphetamine sulfate prescriptions directly to consumers.

• Prescriptions & Usage: The primary indication is ADHD, with an increased trend in adult prescriptions. Off-label use is minimal but present in certain cognitive enhancement contexts.

What Are the Regulatory and Policy Trends Impacting Markets?

• Regulatory Oversight: U.S. DEA quotas limit annual production to approximately 80,000 kilograms for amphetamine salts, with some revisions reflecting market demand and addiction concerns. The quotas often tighten in response to abuse patterns reported in the Monitoring Derby.

• Legal Restrictions: Increasing use of Prescription Drug Monitoring Programs (PDMPs) reduces diversion and illicit use but can also impact legitimate prescriptions, possibly affecting manufacturing volumes marginally.

• International Policies: Countries like Canada and Australia impose stricter controls, which may influence export flows and manufacturing planning.

• Potential Reforms: Legislative discussions regarding rescheduling or decriminalization could alter demand dynamics, but as of 2023, no significant shifts have occurred.

What Is the Financial Trajectory of Amphhetamine Sulfate?

The market has shown consistent growth:

• Historical Growth Rate: Compound annual growth rate (CAGR) of 4-6% over the past five years, driven by increased ADHD diagnoses and expanded adult off-label use.

• Pricing Trends: Average wholesale price (AWP) for generic amphetamine sulfate tablets ranges from $0.10 to $0.50 per milligram, with brand-name formulations commanding higher prices.

• Profit Margins: Manufacturers report gross margins between 35-45%, influenced by manufacturing costs, regulatory fees, and patent status.

• Supply Chain Factors: Raw material procurement, especially for precursor chemicals like phenylacetone, can cause volatility in production costs.

• Market Drivers: Increased awareness and diagnosis of ADHD, stable regulatory environment, and consistent prescription rates support steady revenue streams.

• Risks: Potential regulatory crackdowns, abuse and diversion issues, and patent expirations threaten new revenue growth avenues.

What Are Key Competitive and Market Challenges?

• Regulatory Crackdowns: Heightened international controls and potential rescheduling could reduce supply flexibility.

• Abuse and Diversion: The high abuse potential results in regulatory restrictions impacting production quotas and prescribing practices.

• Patent and Generic Competition: Most formulations are off-patent, leading to intense price competition and margin compression.

• Market Saturation: High prescription volumes limit growth potential unless new indications or formulations are developed.

---

Key Takeaways

• The global market for amphetamine sulfate is approximately $3-5 billion, with US sales accounting for the majority.

• Annual production in the US is capped around 80,000 kg due to DEA quotas, impacting supply and pricing.

• Growth is driven by increased ADHD diagnoses and adult use, with estimated CAGR of 4-6%.

• Price pressures from generics are offset by regulatory costs and diversion control measures.

• Future growth may depend on regulatory shifts, new formulations, or expanded indications.

---

FAQs

1. How are regulatory policies affecting the supply of amphetamine sulfate?
Regulatory agencies like the DEA set production quotas based on abuse trends and medical need, limiting manufacturing volumes and influencing supply stability. Stricter controls can reduce diversion but may also constrain legitimate medical distribution.

2. What are the main regions influencing the global market?
The U.S. dominates the market with around 60% of global production and sales. Europe, China, and Australia are significant, with regulations impacting production and import/export flows.

3. How does patent status influence market dynamics?
Most formulations are off-patent, leading to price competition among generics. Limited innovation in formulations constrains revenue growth, although new extended-release versions have marginally expanded market options.

4. What are the projected growth drivers for the next five years?
Increased adult ADHD diagnosis and off-label use, coupled with steady prescription rates, underpin growth. Regulatory stability and expansion into new territories or formulations could further support this trend.

5. Are there emerging risks to the market?
Yes; regulatory tightening, abuse prevention measures, and potential shifts in legal status pose risks. Supply chain disruptions for precursor chemicals could also impact production.

---

Sources

1. DEA. (2022). Annual Aggregate Production Quotas for Controlled Substances, 21 CFR Parts 1300-1308.
2. IQVIA. (2023). Prescription Data and Market Insights.
3. European Medicines Agency. (2022). Regulatory guidelines on stimulant medications.
4. U.S. FDA. (2022). Drug Approvals and Labeling.
5. MarketWatch. (2023). Pharmaceutical stimulants market analysis and forecasts.

[1] U.S. DEA. Annual quotas report 2022.